Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Psoriasis Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

101 recruiting trials for Psoriasis. Eligibility criteria explained in plain English.

TrialFinderData lists 101 Psoriasis clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Across the trials that carry a phase, Phase 4 is the largest group at 30% (12 studies); the largest phase groups are Phase 4: 12, Phase 3: 12, Phase 1: 6, Phase 2: 6.

Research is led by Bristol-Myers Squibb (5), Psoriasis Treatment Center of Central New Jersey (4), Cairo University (3), among the most active sponsors registered for these trials.

The most frequently studied intervention is Placebo (other, 12 trials), followed by Deucravacitinib, Methotrexate.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
101
Total Trials
101
Recruiting Now
12
Phase 3 Trials
10
Sponsors

Track Psoriasis trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGNCT07289399

Is There a Benefit From Addition of Treadmill Walking to Diet Restriction in Psoriasis Women With PCOS?

Women with psoriasis usually develop many complications including polysyctic ovarian syndrome (PCOS). Nowdays, diet restriction combimed with phsyical exercises may improve both...

Sponsor: Cairo UniversityEnrolling: 401 location
RECRUITINGNCT04806620

Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research

The unhide® Project is a non-interventional, longitudinal research study designed to establish a secure data repository of demographic, health, and lifestyle information from...

Sponsor: Brain Inflammation CollaborativeEnrolling: 100001 location
RECRUITINGNCT04751396

Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for...

This study learn how easily patients can use an educational tool that will be created for patients with melanoma and pre-existing autoimmune diseases who receive or will receive...

Sponsor: M.D. Anderson Cancer CenterEnrolling: 1251 location
RECRUITINGNCT04191395

Evolution and Treatments of Chronic Inflammatory Systemic Diseases

Patients with chronic inflammatory diseases (CID) followed in gastroenterology, dermatology and rheumatology have physiopathological, epidemiological and therapeutic focal points....

Sponsor: Centre Hospitalier Universitaire de BesanconEnrolling: 30001 location
RECRUITINGNCT06599411

Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic...

Chronic inflammatory skin diseases constitute a heterogeneous group of pathologies. They affect the skin but also other organs (joints, lungs, muscles, etc.). Their prognosis and...

Sponsor: Assistance Publique - Hôpitaux de ParisEnrolling: 8301 location
RECRUITINGPhase 1NCT05725876

Quantitative Fluorescence Molecular Imaging of Ustekinumab-800CW to Elucidate the Drug Distribution Throughout Inflamed...

Crohn's Disease (CD) and psoriasis are chronic inflammatory diseases. Ustekinumab is a humanized monoclonal antibody. Ustekinumab is expensive and primary non-response is high in...

Sponsor: University Medical Center GroningenEnrolling: 561 location
RECRUITINGPhase 4NCT07160231

REDO-JAK: Dose Reduction of Janus Kinase Inhibitors in Patients With Inflammatory Rheumatic Diseases

The goal of this clinical trial is to assess the effectiveness of a disease activity guided dose reduction strategy of Janus kinase inhibitor (JAKi) compared to disease activity...

Sponsor: Sint MaartenskliniekEnrolling: 2007 locations
RECRUITINGPhase 3NCT06648772

Efficacy and Safety of Roflumilast Cream 0.3% in Subjects With Plaque Psoriasis: a Phase 3 Study

This study is a multi-center, randomized, double-blind, vehicle-controlled phase III study to evaluate the efficacy, safety, and PK profile of roflumilast cream 0.3% in Chinese...

Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Enrolling: 18920 locations
RECRUITINGPhase 2NCT06865105

Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis

Psoriatic arthritis (PsA) is a type of arthritis that happens when the body's immune system attacks healthy cells and tissues causing joint pain, stiffness, and swelling. Symptoms...

Sponsor: AbbVieEnrolling: 12020 locations
RECRUITINGPhase 3NCT06979453

A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants...

The purpose of this study is to evaluate the efficacy, safety, and drug levels of Deucravacitinib (BMS-986165) in adolescent participants with moderate to severe plaque psoriasis

Sponsor: Bristol-Myers SquibbEnrolling: 36620 locations
RECRUITINGNCT07648602

PPD™ CorEvitas™ Psoriasis (PSO) Early Treatment Response Non-Interventional Study

This is a 24-week prospective, single-arm cohort, study of patients initiating advanced therapy for the treatment of moderate-to-severe plaque PSO. Eligible patients must be...

Sponsor: CorEvitasEnrolling: 25002 locations
RECRUITINGPhase 4NCT06454188

A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritis

A Randomized, Placebo-controlled, Multicenter, Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients with Active Psoriatic Arthritis (UP-SPOUT)

Sponsor: CARE ARTHRITIS LTD.Enrolling: 1005 locations
RECRUITINGNCT06696027

AYLo - AutoimmunitY and Loss of y

The AYLo study (AutoimmunitY and Loss of y - Investigating the Role of Hematopoietic Mutations and Mosaic Mutation in the Y Chromosome in Autoimmune Rheumatologic Diseases) aims...

Sponsor: University of BonnEnrolling: 5001 location
RECRUITINGPhase 1NCT07024602

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of ASC50 Tables in...

This is a phase I, randomized, double-blind, placebo-controlled, single and multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics,...

Sponsor: Ascletis Pharma (China) Co., LimitedEnrolling: 941 location
RECRUITINGNCT06029257

A Study of Tildrakizumab in the Treatment of Genital Psoriasis (CZATCH-Genital-PsO)

The main aim of this study is to check the safety and effectiveness of tildrakizumab regarding the alleviation of symptoms in the genital area after administration according to...

Sponsor: Almirall, S.A.Enrolling: 1101 location
RECRUITINGNCT04731831

Characterization of Immunogenicity of TNF Inhibitors in Arthritis Patients With Poorer Treatment Response.

The aim of the study is to explore whether the influence of gender, tobacco smoking and obesity on treatment response in tumor necrosis factor inhibitors (TNFIs) can be explained...

Sponsor: Aalborg University HospitalEnrolling: 1201 location
RECRUITINGPhase 3NCT06671483

A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines

Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin in people who have psoriasis (PsO). The main aim of the study is to know how well...

Sponsor: TakedaEnrolling: 108820 locations
RECRUITINGNCT07529236

Digestive Evolution of Children With Crohn's Disease or Ulcerative Colitis Whose Anti-TNFα Treatment Was Switched to...

Inflammatory bowel diseases (IBD) include Crohn's disease (CD) and ulcerative colitis (UC). They cause abdominal pain and chronic diarrhea and/or rectal bleeding, which can lead...

Sponsor: Centre Hospitalier Universitaire de NiceEnrolling: 401 location
RECRUITINGNCT04334031

Deployment o the Multidisciplinary Prospective Cohort Imminent

Immune-mediated inflammatory diseases (IMIDs) most often affect young patients and have high impact on morbidity and mortality with a significant alteration in the quality of life...

Sponsor: University Hospital, LilleEnrolling: 22001 location
RECRUITINGNCT06382987

A Study of the Comparative Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in Japan (RePhlect)

This is a prospective, observational, real-world study of adult participants in Japan with physician-reported diagnosis of plaque psoriasis treated with deucravacitinib or...

Sponsor: Bristol-Myers SquibbEnrolling: 6002 locations
RECRUITINGNCT07234591

A Study to Evaluate Effectiveness and Safety of a TYK2 Inhibitor in Subjects With Moderate to Severe Plaque Psoriasis

A Study to evaluate efficacy and safety in subjects with moderate to severe Plaque Psoriasis treated with a TYK2 Inhibitor for 12 weeks

Sponsor: Usynova Pharmaceuticals Ltd.Enrolling: 1401 location
RECRUITINGPhase 2NCT07251998

Efficacy and Safety of ICP-332 Versus Placebo in Participants With Moderate to Severe Plaque Psoriasis

The purpose of this study is to compare the efficacy and safety of ICP-332 to placebo in participants with moderate-to-severe plaque psoriasis.

Sponsor: Beijing InnoCare Pharma Tech Co., Ltd.Enrolling: 1721 location
RECRUITINGNCT06399432

Mediterranean Diet vs no Dietary Intervention for Improving Signs and Symptoms of Psoriasis in Patients Treated With...

In this study, participants will have 3 or 4 total study visits over approximately 10 total weeks. There is a two week medication washout period in between the 1st and 2nd visits....

Sponsor: University Hospitals Cleveland Medical CenterEnrolling: 361 location
RECRUITINGNCT04846959

Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab Exposed...

The objective of this registry is to compare outcomes of risankizumab-exposed pregnancies with those of pregnancies that were not exposed to risankizumab among women with plaque...

Sponsor: AbbVieEnrolling: 8182 locations
RECRUITINGPhase 3NCT06807424

A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive...

The purpose of this study is to evaluate the efficacy of icotrokinra (JNJ-77242113) compared to placebo in biologic-experienced and biologic-naive participants with active...

Sponsor: Janssen Research & Development, LLCEnrolling: 75020 locations
RECRUITINGPhase 3NCT04772079

A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants...

The purpose of this pediatric study is to evaluate the drug levels, efficacy and safety of Deucravacitinib in children and adolescent participants aged 4 to \<18 years with...

Sponsor: Bristol-Myers SquibbEnrolling: 15320 locations
RECRUITINGNCT05503875

Immunoclassification of Psoriasis: a Strategy for Precision Medicine

Through the combination of clinical manifestations and omics, the investigators aim to explore the skin cell atlas in different stages of psoriasis lesions, establish a clinical...

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang UniversityEnrolling: 1001 location
RECRUITINGPhase 2NCT06380907

A Phase 2 Study of ZL-1102 in Patients With Chronic Plaque Psoriasis

A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Dose-Ranging, Phase 2 Study to Evaluate the Efficacy and Safety of Different Doses of ZL-1102 Topical gel (A Human VH...

Sponsor: Zai Lab (Hong Kong), Ltd.Enrolling: 25010 locations
RECRUITINGNCT05644782

Dietary Approach to Mild-to-moderate Psoriasis

Psoriasis is a systemic chronic inflammatory immune-mediated disease whose etiopathogenetic mechanisms involve genetic predisposition, and immunological and environmental factors....

Sponsor: University of PalermoEnrolling: 823 locations
RECRUITINGNCT07220824

A Study of Guselkumab in Participants With Psoriatic Arthritis (PsA) in a Real-World Setting

The purpose of this study is to assess how well guselkumab works in improving symptoms of psoriatic arthritis (an inflammatory disease that affects the joints in participants with...

Sponsor: Janssen Research & Development, LLCEnrolling: 20020 locations
RECRUITINGNCT06030076

A Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes...

The main aim of this study is to assess the effects of switching from another biologic to tildrakizumab on patient-reported outcomes and to assess psoriasis intensity, patient's...

Sponsor: Almirall, S.A.Enrolling: 501 location
RECRUITINGNCT06299917

WORK-ON Vocational Rehabilitation for People with Inflammatory Arthritis

People with chronic inflammatory arthritis (IA) (rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis), often have a reduced work ability. Up to 40% lose their...

Sponsor: The Danish Center for Expertise in RheumatologyEnrolling: 561 location
RECRUITINGNCT07000916

Medical Follow-up of New Cases of Polyarthritis in Children and Young Adults

Population: Juvenile idiopathic arthritis (JIA), rheumatoid arthritis (RA) and seronegative / psoriatic / undifferentiated arthritis (UA), systemic lupus erythematosus (SLE) or...

Sponsor: Université Catholique de LouvainEnrolling: 10001 location
RECRUITINGPhase 3NCT07426120

Efficacy and Safety of a Botanical Total Coumarin (TC) Cream in Treating Patients With Psoriasis Vulgaris...

The goal of this clinical trial is to learn if a botanical Total Coumarin topical cream (TC Cream) works to treat psoriasis in adults. It will also learn about the safety of the...

Sponsor: Psoriasis Research Institute of GuangzhouEnrolling: 3001 location
RECRUITINGPhase 3NCT06477237

Study of Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis

This is a multicenter, randomized, double-blind, placebo-controlled, phase III clinical study which is designed to determine the efficacy, safety, immunogenicity and...

Sponsor: Huabo Biopharm Co., Ltd.Enrolling: 40020 locations
RECRUITINGNCT06893913

Effect of Addition of Pyramidal Exercise to Intermittent Fasting on Dryness of Eye in Pre-diabetic Psoriasis Patients

insulin resistant psoriatic obese patients may complain problems of dryness of eye. Intermittent fasting may improve dryness of eye, obesity, insulin resistance, and psoriasis....

Sponsor: Cairo UniversityEnrolling: 401 location
RECRUITINGPhase 2NCT07314060

A Clinical Trial of TQH2929 Injection in Patients With Acute Flare-up of Generalized Pustular Psoriasis

This is a multicenter, randomized, double-blind, placebo-controlled phase II clinical study, all subjects need to use TQH2929 injection/placebo. The aim was to demonstrate the...

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Enrolling: 3620 locations
RECRUITINGPhase 4NCT04347473

ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis.

Patient with moderate-to-severe plaque psoriasis will receive Ilumya with or without Halog ointment.

Sponsor: Psoriasis Treatment Center of Central New JerseyEnrolling: 251 location
RECRUITINGNCT06764693

An Ex-US Study to Assess Treatment Persistence With Risankizumab in Adult Participants With Psoriatic Arthritis

Psoriatic arthritis (PsA) is a type of arthritis (swelling and stiffness in the joints) that is frequently seen in trial participants who also have the skin condition psoriasis....

Sponsor: AbbVieEnrolling: 120020 locations
RECRUITINGNCT05744466

A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque...

The purpose of this study is to understand the comparative effectiveness of deucravacitinib versus apremilast in adults with plaque psoriasis.

Sponsor: Bristol-Myers SquibbEnrolling: 15001 location
RECRUITINGPhase 4NCT04537689

Outcomes With Treatment and Withdraw of Ixekizumab in Patients With Plaque Psoriasis

Psoriasis (PsO) is a systemic immune disease that affect 2-4% of the population worldwide. PsO causes tremendous burden in terms of quality of life, psychological impact,...

Sponsor: Singapore General HospitalEnrolling: 401 location
RECRUITINGNCT05122039

ProspectIve Cohort psoriASiS fOllow-up (PICASSO)

The main purpose of the PICASSO-project is to facilitate future psoriasis-research in dermatology. This register biobank will enable us to perform research in the field of...

Sponsor: Universitaire Ziekenhuizen KU LeuvenEnrolling: 2001 location
RECRUITINGNCT04402086

Rheumatology Patient Registry and Biorepository

To facilitate clinical, basic science, and translational research projects involving the study of rheumatic diseases.

Sponsor: Yale UniversityEnrolling: 50001 location
RECRUITINGNCT06730334

Prospective Study of Classification and Activity Assessment of Psoriatic Arthritis Based on Power Doppler (PD)...

Psoriatic arthritis (PsA) is a complex inflammatory disease with heterogeneous clinical features, which complicates psoriasis in 30% of patients. PsA involves multiple tissues and...

Sponsor: Nanjing Medical UniversityEnrolling: 4002 locations
RECRUITINGNCT07132333

Molecular Inflammation Board at the Center for Personalized Medicine

Molecular Inflammation Board at the Center for Personalized Medicine

Sponsor: University Hospital TuebingenEnrolling: 30001 location
RECRUITINGPhase 3NCT06671496

A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines

Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin in people who have psoriasis (PsO). The main aim of the study is to know how well...

Sponsor: TakedaEnrolling: 60020 locations
RECRUITINGPhase 4NCT03827876

Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis

4 weeks of adjunctive therapy of Enstilar® QD followed by 12 weeks QOD to patients with 2-10% BSA who are receiving etanercept or adalimumab for at least 24 weeks

Sponsor: Psoriasis Treatment Center of Central New JerseyEnrolling: 301 location
RECRUITINGPhase 4NCT06857942

A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in...

The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe...

Sponsor: Eli Lilly and CompanyEnrolling: 20020 locations
RECRUITINGNCT07532486

A Study to Evaluate Comparative Efficacy and Safety of Guselkumab in High-dose and Extended-interval Versus...

The purpose of this study is to evaluate the efficacy, safety, tolerability and drug survival of guselkumab in high-dose and extended-interval versus standard-dose in Chinese...

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang UniversityEnrolling: 4001 location
RECRUITINGNCT02418442

Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry

Continuation of the CARRA Registry as described in the protocol will support data collection on patients with pediatric-onset rheumatic diseases. The CARRA Registry will form the...

Sponsor: Duke UniversityEnrolling: 2000020 locations

Showing 50 of 101 trials.Search all Psoriasis trials

Frequently Asked Questions

There are currently 101 clinical trials for Psoriasis, with 101 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Psoriasis, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 12 Phase 3 trials for Psoriasis, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.